Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion

British Journal of Ophthalmology

Volumn 96, Issue 11, 2012, Pages 1426-1430

  Lee, Won June ^a   Kang, Min Ho ^b   Seong, Mincheol ^a   Cho, Hee Yoon ^a  

^a Hanyang University College of Medicine   (South Korea)

^b Hanyang University Guri Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYTOKINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR AA; TRANSFORMING GROWTH FACTOR ALPHA; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RESPONSE; DIABETIC MACULAR EDEMA; DISEASE SEVERITY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA ISCHEMIA; RETINA VEIN OCCLUSION;

AGED; AQUEOUS HUMOR; BIOLOGICAL MARKERS; CYTOKINES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION;

EID: 84868141471     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2012-301913     Document Type: Article

References (25)

1. Scholl S, Kirchhof J, Augustin AJ. Pathophysiology of Macular Edema. Ophthalmologica 2010;224:8-15.
2. Ehrlich R, Harris A, Ciulla TA, et al. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmologica 2010;88:279-91.
3. Astam N, Batioǧlu F, Özmert E. Short-term efficacy of intravitreal bevacizumab for the treatment of macular edema due to diabetic retinopathy and retinal vein occlusion. Int Ophthalmol 2008;29:343-8.
4. Stahl A, Agostini H, Hansen LL, Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefe's Arch Clin Exp Ophthalmol 2007;245:1429-36.
5. Cheng KC, Wu WC, Chen KJ. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion. Eye 2009;23:2023-33.
6. Paccola L, Costa RA, Folgosa MS, et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2007;92:76-80.
7. Shimura M, Nakazawa T, Yasuda K, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic Macular Edema. Am J Ophthalmol 2008;145:854-61.e3.
8. Oh IK, Kim S-W, Oh J, et al. Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy. Curr Eye Res 2010;35:1116-27.
9. Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic Macular Edema. Am J Ophthalmol 2011;152:686-94.
10. Suzuki Y, Nakazawa M, Suzuki K, et al. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol 2011;55:256-63.
11. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest OphthalmolVis Sci 2008;50:1025-32.
12. Kaneda S, Miyazaki D, Sasaki Si, et al. Multivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment. Invest Ophthalmol Vis Sci 2011;52:2982-8.
13. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 2006;22:42-8.
14. Terui T, Kondo M, Sugita T, et al. Changes in areas of capillary nonperfusion after intravitreal injection of bevacizumab in eyes with branch retinal vein occlusion. Retina 2011;31:1068-74.
15. Fulton RJ, McDade RL, Smith PL, et al. Advanced multiplexed analysis with the FlowMetrix system. Clin Chem 1997;43:1749-56.
16. Maier R, Weger M, Haller-Schober EM, et al. Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients. Mol Vis 2008;14:637-43.
17. Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods 2000;243:243-55.
18. Holzinger C, Weissinger E, Zuckermann A, et al. Effects of interleukin-1, -2, -4, -6, interferon-gamma and granulocyte/macrophage colony stimulating factor on human vascular endothelial cells. Immunol Lett 1993;35:109-17.
19. Matsushima K, Larsen CG, DuBois GC, et al. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 1989;169:1485-90.
20. Oppenheim JJ, Zachariae CO, Mukaida N, et al. Properties of the novel proinflammatory supergene 'intercrine' cytokine family. Annu Rev Immunol 1991;9:617-48.
21. Rollins BJ, Walz A, Baggiolini M. Recombinant human MCP-1/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. Blood 1991;78:1112-6.
22. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996; 271:17779-84.
23. Taub DD, Anver M, Oppenheim JJ, et al. T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J Clin Invest 1996;97:1931-41.
24. Petrovic MG, Korosec P, Kosnik M, et al. Vitreous levels of interleukin-8 in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2007; 143:175-6.
25. Sobel DO, Newsome J. Gamma interferon prevents diabetes in the BB rat. Clin Diagn Lab Immunol 1997;4:764-8.